問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site > 收納受試者人數排名

Search Result

List

6Cases

2016-12-15 - 2020-06-08

Phase III

Not yet recruiting
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Asian Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine

  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Keytruda

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

白禮源
China Medical University Hospital-Taipei

未分科

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2015-10-15 - 2020-06-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

  • Condition/Disease

    Active Systemic Lupus Erythematosus

  • Test Drug

    STELARA

Participate Sites
6Sites

Terminated4Sites

Study ended1Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

2018-11-01 - 2021-12-31

Phase III

A Randomized, Controlled, Double-blind Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis

  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Orelvo (voclosporin)

Participate Sites
4Sites

Terminated2Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

Division of Rheumatology

2017-04-01 - 2019-07-31

Phase III

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Orelvo (voclosporin)

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

Division of Rheumatology

2015-03-01 - 2019-06-30

Phase II/III

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial

  • Condition/Disease

    Chronic Hepatitis C

  • Test Drug

    MK-5172A

Participate Sites
10Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital-Taipei

未分科

彭成元
China Medical University Hospital

Digestive System Department

2015-07-01 - 2026-05-29

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence

  • Condition/Disease

    Melanoma

  • Test Drug

    Nivolumab, Ipilimumab

Participate Sites
4Sites

Terminated3Sites

林振源
China Medical University Hospital-Taipei

未分科

林振源
China Medical University Hospital

Division of Hematology & Oncology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB